Holen Sie sich die Stockscreener-App
714.89
0.82%
5.79
Handel nachbörslich:
716.55
1.66
+0.23%
Schlusskurs vom Vortag:
$709.10
Offen:
$709.29
24-Stunden-Volumen:
558.93K
Relative Volume:
0.81
Marktkapitalisierung:
$74.95B
Einnahmen:
$14.92B
Nettoeinkommen (Verlust:
$4.42B
KGV:
17.42
EPS:
41.0422
Netto-Cashflow:
$3.79B
1W Leistung:
+1.92%
1M Leistung:
-7.82%
6M Leistung:
+8.72%
1J Leistung:
+30.53%
1-Tages-Spanne:
$708.36
$717.99
1-Wochen-Bereich:
$699.23
$726.16
52-Wochen-Spanne:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2026-03-06 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Hochstufung | BofA Securities | Underperform → Buy |
| 2025-12-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Eingeleitet | HSBC Securities | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-14 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Herabstufung | Argus | Buy → Hold |
| 2025-05-30 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Eingeleitet | Bernstein | Outperform |
| 2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Bestätigt | Oppenheimer | Perform |
| 2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-12-07 | Fortgesetzt | Cowen | Market Perform |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
| 2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-11 | Hochstufung | Argus | Hold → Buy |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Hold |
| 2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Regeneron’s Otarmeni Win Links Gene Therapy Ambition With ESG Commitments - Yahoo Finance
Generali Asset Management SPA SGR Reduces Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
F m Investments LLC Has $17.61 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharma stock (US75886F1075): Biotech giant trades near $715 after modest gain on Friday - AD HOC NEWS
Follow The Sun - the-sun.com
Assessing Regeneron (REGN) After Recent Share Price Weakness And Strong Valuation Signals - simplywall.st
Gene Therapy Briefs: Regeneron Wins FDA Approval for First Neurosensory Gene Therapy - Genetic Engineering and Biotechnology News
Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There. - The Motley Fool
Is This Biotech Stock a Buy After a Groundbreaking Approval? - AOL.com
Only 8 biotech companies made this global responsibility index — Regeneron did - Stock Titan
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Lmcg Investments LLC Grows Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by K.J. Harrison & Partners Inc - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Kiniksa hits 52-week high as Regeneron-partnered lead product drives Q1 beat - MSN
Bluebird Wealth Management LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
The top 12 companies hiring in biopharma now - BioSpace
Neurotrophic Keratitis Treatment Market Size Accelerating - openPR.com
Bayer to Acquire Perfuse for up to $2.45B, Seeing Ophthalmology Opportunity - Genetic Engineering and Biotechnology News
Regeneron drops despite Q1 beat, $3B share buyback program - MSN
TD Cowen Initiates Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Announces Target Price $960 - 富途牛牛
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Swedbank AB - MarketBeat
Does Regeneron’s Gene Therapy Milestone and Buyback Shift the Bull Case For Regeneron Pharmaceuticals (REGN)? - simplywall.st
Insider Sell: Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN) - GuruFocus
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MSN
Regeneron (REGN) Dupixent Phase 4 Trial Results Show Improved Esophageal Function in EoE - Yahoo Finance
REGN Stock Quote Price and Forecast - CNN
Chronic Spontaneous Urticaria Market Size 2026-2033 Industry - openPR.com
Varma Mutual Pension Insurance Co Sells 2,800 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Dupixent shows improved esophageal function in EoE trial - Investing.com
Dupixent shows improved esophageal function in EoE trial By Investing.com - Investing.com Canada
Regeneron wins FDA approval for hearing loss therapy - MSN
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Horizon Investments LLC - MarketBeat
Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells 100 Shares of Stock - MarketBeat
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $900 - Moomoo
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Seizert Capital Partners LLC - MarketBeat
Kornitzer Capital Management Inc. KS Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
How The Regeneron (REGN) Narrative Is Shifting With Dupixent, Eylea And Pipeline Developments - Yahoo Finance
Cash-Rich Companies: One to Watch, Two to Sell in 2026 - IndexBox
Bellecapital International Ltd. Decreases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
PKO Investment Management Joint Stock Co Has $3.74 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Strs Ohio Sells 2,589 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
PFA Pension Forsikringsaktieselskab Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Fifth Third Bancorp Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Piper Sandler Rates Regeneron (REGN) Overweight on Oncology Growth - Insider Monkey
Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing? - The Motley Fool
Del Sette Capital Management LLC Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Weakness - simplywall.st
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years - Sahm
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Regeneron Pharmaceuticals Inc-Aktie (REGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RYAN ARTHUR F | Director |
Apr 01 '26 |
Sale |
777.27 |
100 |
77,727 |
17,603 |
| RYAN ARTHUR F | Director |
Mar 02 '26 |
Sale |
785.50 |
100 |
78,550 |
17,703 |
| Zoghbi Huda Y | Director |
Feb 19 '26 |
Option Exercise |
376.69 |
1,638 |
617,018 |
3,341 |
| Zoghbi Huda Y | Director |
Feb 19 '26 |
Sale |
781.33 |
1,638 |
1,279,812 |
1,703 |
0.65%
1.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):